New Ester‐Containing Azole Derivatives With Potent Anti‐ Candida Effects: Synthesis, Antifungal Susceptibility, Cytotoxicity, and Molecular Modeling Studies
Drug Development Research · 2024
DOI: 10.1002/ddr.70021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, 2024. Verfasst von Yusuf Ataker und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey. Hauptthemen laut MEDLINE: Antifungal Agents, Azoles, Microbial Sensitivity Tests, Candida. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: This study was funded by 2209 Program of the Scientific and Technological Research Council of Turkey (TÜBİTAK) (grant no: 1919B012205352)..
Abstract (Originalsprache)
Mortalities due to mycoses have dramatically increased with the emergence of drug‐resistant strains and growing immune‐compromised populations globally. Azole antifungals have been the first choice against fungal infections of a wide spectrum and several azole derivatives with ester function were reported for their potentially promising and favorable activity against Candida spp. In this study, we designed and synthesized a series of 1‐(aryl)−2‐(1 H ‐imidazol‐1‐yl/1 H ‐1,2,4‐triazol‐1‐yl)ethyl esters, and tested them against seven reference Candida strains using EUCAST reference microdilution method. Among the series, 6a , 6d , and 6g proved highly potent in vitro compared to fluconazole; especially against Candida albicans and Candida tropicalis with minimum inhibitor concentration (MIC) values as low as 0.125 and 0.06 mg/L, respectively, although their activities against Candida krusei and Candida glabrata remained limited. The compounds also showed minimal toxicity to murine fibroblasts according to the in vitro cytotoxicity tests. Molecular modeling predicted 6g as an orally available druglike compound according to all parameters and CYP51 inhibition as the likely mechanism for their antifungal effects. The study underpins the promise of azoles with ester functionality as a potential scaffold for small‐molecule antifungal drug design.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Başkent University, Ankara, Turkey.
- Department of Medical Microbiology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
- Department of Pharmaceutical Toxicology, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey.
ORCID-Profile: Dolunay Gülmez, Suat Sari
Förderung
- This study was funded by 2209 Program of the Scientific and Technological Research Council of Turkey (TÜBİTAK) (grant no: 1919B012205352).
Zitieren
APA
Ataker, Y., Öncü, Ö., Gülmez, D., Sabuncuoğlu, S., Arikan-Akdagli, S., & Sari, S. (2024). New Ester‐Containing Azole Derivatives With Potent Anti‐ Candida Effects: Synthesis, Antifungal Susceptibility, Cytotoxicity, and Molecular Modeling Studies. Drug Development Research. https://doi.org/10.1002/ddr.70021
Vancouver
Ataker Y, Öncü Ö, Gülmez D, Sabuncuoğlu S, Arikan-Akdagli S, Sari S. New Ester‐Containing Azole Derivatives With Potent Anti‐ Candida Effects: Synthesis, Antifungal Susceptibility, Cytotoxicity, and Molecular Modeling Studies. Drug Development Research. 2024. doi:10.1002/ddr.70021
BibTeX
@article{Ataker2024,
author = {Ataker, Yusuf and Öncü, Özge and Gülmez, Dolunay and Sabuncuoğlu, Suna and Arikan-Akdagli, Sevtap and Sari, Suat},
title = {New Ester‐Containing Azole Derivatives With Potent Anti‐ Candida Effects: Synthesis, Antifungal Susceptibility, Cytotoxicity, and Molecular Modeling Studies},
journal = {Drug Development Research},
year = {2024},
doi = {10.1002/ddr.70021}
}
EUVIMED